--- title: "Teladoc Health Stock Pops - Here's Why" type: "News" locale: "en" url: "https://longbridge.com/en/news/278579683.md" description: "Teladoc Health's stock surged after reporting better-than-expected quarterly results, with a loss of 14 cents per share against an anticipated 18 cents loss, and sales of $642.27 million exceeding expectations. However, the company provided cautious guidance for 2026, predicting a loss of 70 cents to $1.10 and sales between $2.47 billion and $2.59 billion. Analysts have mixed views, with Deutsche Bank upgrading the stock to Buy, while others like BTIG and Citigroup remain cautious, lowering price targets. Currently, TDOC is trading at $5.59, showing short-term strength but long-term struggles." datetime: "2026-03-10T14:49:47.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278579683.md) - [en](https://longbridge.com/en/news/278579683.md) - [zh-HK](https://longbridge.com/zh-HK/news/278579683.md) --- # Teladoc Health Stock Pops - Here's Why **Teladoc Health Inc.** (NYSE:TDOC) shares are up on Tuesday. ## TDOC Reported Stronger-Than-Expected Quarterly Results In February, Teladoc Health reported a quarterly loss of 14 cents per share, which was better than the consensus loss of 18 cents. Additionally, sales increased to $642.27 million, surpassing the expected $635.24 million, driven by a 24% rise in other revenue streams, although access fees revenue fell by 4%. Teladoc Health expects the first quarter 2026 loss to be between 35-45 cents compared to the consensus loss of 25 cents, with sales of $598-$620 million versus the consensus of $633.75 million. The telehealth company sees a fiscal 2026 loss of 70 cents to $1.10, with sales of $2.47 billion to $2.59 billion, compared to the consensus of 76 cents and $2.55 billion, respectively. ## Analyst Reaction **Deutsche Bank** on Monday upgraded the virtual health care provider, citing a compelling valuation and a potential exit scenario. Deutsche upgraded TDOC from Hold to Buy, with a price forecast of $11 After the fourth quarter earnings, **BTIG** updated its earnings model for Teladoc Health. David Larsen on Monday wrote, “While results in the quarter were decent, we remain generally cautious on TDOC.” Larsen wrote that “Given a difficult macro environment, a seemingly saturated tele-health market, and a highly competitive behavioral health market, we remain cautious on TDOC.” BTIG maintains the Neutral rating on Teladoc Health. **Oppenheimer** reiterated Teladoc Health with an Outperform and lowered the price target from $12 to $7. **Citigroup** maintained Teladoc Health with a Neutral and lowered the price target from $9 to $6. **Piper Sandler** reiterated Teladoc Health with an Overweight rating and lowered the price target from $12 to $9. **BMO Capital** maintained Teladoc with a Market Perform and lowered the price target from $8 to $5. **TD Cowen** maintained the stock with a Hold and lowered the price target from $8 to $6. **Leerink Partners** maintained Teladoc Health with a Market Perform and lowered the price target from $8.5 to $5.5. **Canaccord Genuity** kept the Buy rating and lowered the price target from $12 to $10. ## TDOC Shows Short-Term Strength Amid Long-Term Struggles The stock is currently trading 21.8% above its 20-day simple moving average (SMA) but is 12.5% below its 100-day SMA, indicating some short-term strength while struggling in the longer term. Over the past 12 months, shares have decreased 40.65% and are currently positioned closer to their 52-week lows than highs. The RSI is at 52.22, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold at this time. Meanwhile, MACD is at -0.1341, above its signal line at -0.2551, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum. Traders should watch for potential breakouts or reversals as the stock navigates its current technical landscape. - **Key Resistance**: $6.50 - **Key Support**: $5.00 **TDOC Price Action:** Teladoc Health shares were up 5.57% at $5.59 at the time of publication on Tuesday, according to Benzinga Pro data. _Image Via Teladoc_ ### Related Stocks - [FDHT.US](https://longbridge.com/en/quote/FDHT.US.md) - [HEAL.US](https://longbridge.com/en/quote/HEAL.US.md) - [EDOC.US](https://longbridge.com/en/quote/EDOC.US.md) - [TDOC.US](https://longbridge.com/en/quote/TDOC.US.md) ## Related News & Research - [12:20 ETDid Teladoc Health, Inc. Insiders Breach their Fiduciary Duties to Shareholders?](https://longbridge.com/en/news/282570246.md) - [Activist Pineal Capital pushes Teladoc to consider split, other changes to boost value](https://longbridge.com/en/news/281248662.md) - [Teladoc Health (NYSE:TDOC) Upgraded at Deutsche Bank Aktiengesellschaft](https://longbridge.com/en/news/278564127.md) - [Argus Research Reaffirms Their Buy Rating on Owens Corning (OC)](https://longbridge.com/en/news/282565916.md) - [Owens Corning (OC) Valuation Check After Recent Share Price Rebound](https://longbridge.com/en/news/282393058.md)